The Vision for Tomorrow Foundation is proud to support ongoing work with Peter A. Netland, MD, PhD, Vernah Scott Moyston Professor & Chair, Glaucoma Fellowship Program Director and Robert M. Grainger, PhD, Professor of Biology, both at the University of Virginia. They, along with their team, recently performed a retrospective,...

Vision for Tomorrow is proud to partner with the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), to fund a study attempting to identify drugs that will improve vision in people with oculocutaneous albinism (OCA)....

Vision for Tomorrow is proud to partner with the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), to fund a study attempting to identify drugs that will improve vision in people with oculocutaneous albinism (OCA)....

Phase 2 Proof-of-Concept Study for ataluren in Nonsense Mutation Aniridia PTC Therapeutics’ STAR study is a Phase 2 proof-of-concept study of ataluren, an orally administered, first-in-class, protein restoration therapy for the treatment of nonsense mutation aniridia, a rare genetic disorder...

Phase 2 Proof-of-Concept Study for ataluren in Nonsense Mutation Aniridia PTC Therapeutics’ STAR study is a Phase 2 proof-of-concept study of ataluren, an orally administered, first-in-class, protein restoration therapy for the treatment of nonsense mutation aniridia, a rare genetic disorder...